Stanford researchers have discovered RNA signatures that can be used to predict patient outcomes and identify optimal treatments in acute myeloid leukemia.
The cost of DNA and RNA sequencing have decreased in recent years to aid effective research and clinical applications; however, the labor time and throughput of preparing DNA and RNA sequencing libraries remains a challenge.
Stanford researchers have developed a new, low-cost method for tumor methylation profiling that enables tumor classification even from low amounts of fragmented DNA characteristic of liquid biopsies.
Liquid biopsies have emerged as a groundbreaking approach in cancer diagnostics, enabling the detection of DNA shed by cancer cells through a simple blood test. However, cancer cells also shed RNA into the blood.
Stanford researchers have formulated a first in line framework called EcoTyper which systematically profiles the tumor microenvironment (TME) cell states in multiple solid tumor types, providing a platform for effective personalized cancer decisions.
Metagenomic sequencing offers a powerful approach for the comprehensive monitoring and detection of pathogenic bacteria in food, clinical samples, and the environment.